The treatment of patients with late-stage epidermal growth factor receptor (EGFR) sensitizing mutations positive NSCLC using tyrosine kinase inhibitors (TKIs) is exemplified as precision medicine which takes into account the individual variability in the genes, environment, and lifestyle of each patient. This evidence concerns the gene EGFR and non-small cell lung carcinoma.